SCImago Journal & Country Rank
This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE)
2020, Volume 36, Number 1, Page(s) 048-063     
[ PDF ] [ Similar Articles ]
DOI: 10.5146/tjpath.2019.01463
Relation Between Immunohistochemical Expression of Hippo Pathway Effectors and Chronic Hepatitis Induced Fibrosis in Egyptian Patients
Rania Abdallah ABDALLAH1, Mohammad Ibrahim SHABAN1, Doha Maher TAIE2, Nancy Youssef ASAAD1, Aya Hamdy Abd El Bary BADR2
1Department of Pathology, Menoufia University Faculty of Medicine, SHEBEIN ELKOM, EGYPT
2Department of Pathology, Menoufia University, Liver Institute, MENOUFIA, EGYPT
Keywords: Yes-associated protein, Transcriptional coactivator with PDZ-binding motif, Chronic hepatitis, Fibrosis

Objective: Chronic hepatitis is a global health problem especially in Egypt. Hepatic fibrosis is a common end clinical manifestation of many chronic liver diseases. Although it is a wound-healing process, excessive accumulation of fibrillary collagen leads to architectural damage, cirrhosis and liver failure. Recently, a few studies have linked Hippo pathway effectors of yes-associated protein (YAP) and its paralog transcriptional coactivator with PDZ-binding motif (TAZ) to extracellular matrix deposition and ongoing fibrosis.

Material and Method: Immunohistochemical expression of YAP and TAZ were analyzed in 121 liver needle core biopsies (91 core biopsies of chronic viral hepatitis, 20 biopsies of autoimmune hepatitis and 10 normal liver cores).

Results: YAP and TAZ nuclear localization was absent in all normal liver cores. Autoimmune hepatitis cases showed higher nuclear expression of both YAP and TAZ in comparison to chronic viral cases. YAP and TAZ expression were correlated with severity of hepatocyte injury together with fibrosis in chronic viral cases but these correlations were absent in AIH cases despite the pronounced increase of YAP and TAZ nuclear localization.

Conclusion: The correlation between Hippo effectors activation and fibrosis in chronic viral hepatitis patients emphasize their role in the development and advancement of hepatic scarring and highlight the use of both YAP and TAZ as novel targets to ameliorate liver fibrosis.

[ PDF ] [ Similar Articles ]